The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Spiroplatin is a second generation metallodrug and analgue for cisplatin, developed for cancer therapy. Spiroplatin induces DNA cross-links, thereby
inhibiting DNA replication and RNA and protein synthesis. Similar to
other platinum compounds, this agent has been shown to be mutagenic and